Arvin Abueg, MD
Family Medicine · Canton, MONPI 1770814014
Payments from drug & device makers
Across 184 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$853
- AstraZeneca$644
- Amgen$301
- Verona Pharma, Inc.$268
- Lilly USA, LLC$232
- Bayer$192
- plus $792 from 13 others
What the payments were for
- Food & beverage$3,283100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 76 | $853 |
| AstraZeneca | 22 | $644 |
| Amgen | 21 | $301 |
| Verona Pharma, Inc. | 12 | $268 |
| Lilly USA, LLC | 14 | $232 |
| Bayer | 10 | $192 |
| Mylan Specialty L.p. | 2 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Novo Nordisk | 6 | $97 |
| Harmony Biosciences LLC | 1 | $91 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| Pfizer | 3 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Exact Sciences | 3 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,283 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 212 | $209,745 |
| TrulicityDulaglutide | 85 | $96,222 |
| EliquisApixaban | 107 | $93,071 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 108 | $76,038 |
| XareltoRivaroxaban | 97 | $74,083 |
| VraylarCariprazine Hcl | 49 | $70,059 |
| FarxigaDapagliflozin Propanediol | 62 | $51,134 |
| MounjaroTirzepatide | 29 | $36,679 |
| RybelsusSemaglutide | 30 | $34,150 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 858 | $32,421 |
| OxycontinOxycodone Hcl | 27 | $25,481 |
| Aimovig AutoinjectorErenumab-Aooe | 31 | $23,493 |
| JanuviaSitagliptin Phosphate | 27 | $18,080 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $16,163 |
| Incruse ElliptaUmeclidinium Bromide | 36 | $16,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $97 | $243,895242 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $232 | $132,901114 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Bevespi Aerosphere | $644 | $131,844181 claims |
| PfizerEliquis | $60 | $93,071107 claims |
| AbbVieVraylar, Linzess | $853 | $79,02066 claims |
| BayerKerendia | $192 | $14,84312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Canton
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.